ALLERGY TREATMENT MARKET ANALYSIS

Market Size and Trends

The global allergy treatment market is estimated to be valued at USD 21.19 Bn in 2024 and is expected to reach USD 34.42 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.

To learn more about this report, request a free sample copy

The global allergy treatment market is witnessing positive trends with rising environmental pollution levels and growing adoption of sedentary lifestyle among people worldwide. Increased air pollution along with higher consumption of fast food and processed food has significantly contributed to the increased prevalence of allergies. Additionally, market players are continuously focusing on developing advanced and effective drugs for treating diverse allergy conditions such as asthma, rhinitis, conjunctivitis, and others. Several pipeline drugs for treating chronic allergic diseases are expected to enter the market soon, thereby propelling the overall growth of the industry during the forecast period

Increasing Availability of Allergen Immunotherapy Solutions

The increasing availability of allergen immunotherapy solutions is one of the factors that is expected to drive the market growth during the forecast period. For instance, in June 2021, Stallergenes Greer, one of the global leaders in allergy immunotherapy, announced that the Alusta, subcutaneous allergen immunotherapy (SCIT) solution for different allergies involving rhinitis, conjunctivitis, rhino conjunctivitis, or asthma is now available in Spain and Italy.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Increasing adoption of inorganic growth strategies, such as collaborations, is expected to drive the market growth over the forecast period. For instance, on January 8, 2024, Inimmune Corporation, a pharmaceutical company, and Intrommune Therapeutics, Inc., a clinical-stage company focused on the development of innovative immunotherapeutics, announced that they had collaborated together to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy.

To learn more about this report, request a free sample copy

The major factors that are expected to hinder the growth of the global allergy treatment market include the termination of clinical trial study. For instance, in November 2022, a clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity I was terminated due to the poor enrollment of subjects. The clinical trial was sponsored by Allergy Therapeutics, a manufacturer of subcutaneous and sublingual immunotherapy treatments.

Market Opportunities – Increasing Research and Development Activities by Key Market Players

Increasing research and development activities by market players is expected to offer lucrative growth opportunities over the forecast period. For instance, in August 2023, Inimmune Corporation (“Inimmune”), a clinical-stage company focused on the development of innovative immunotherapeutics, announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential treatment of allergic rhinitis. The phase 1/1b trial is a randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INI-2004 in healthy volunteers and participants with allergic rhinitis (AR).

To learn more about this report, request a free sample copy

The type segment includes eye allergy, asthma, rhinitis, skin allergy, food allergies, and others. The asthma sub-segment is estimated to hold 31.7% of the market share in 2024 owing to the rising prevalence of asthma globally. According to recent estimates by health organizations, over 300 million people suffer from asthma worldwide. The condition is characterized by inflammation of the airways and difficulty in breathing. Conventional treatment of acute asthma involves the use of short-acting beta-agonists to relax bronchial muscles. However, long-term control medications such as inhaled corticosteroids and leukotriene modifiers are essential to prevent recurrent symptoms. The asthma segment is driven by the need for more effective medicines that can better manage symptoms over prolonged use. Several drug makers are investing in research to develop novel biologic drugs targeting specific inflammatory pathways involved in asthma pathophysiology. Monoclonal antibody therapies that block immune system proteins like IgE and IL-5 have shown promising results in clinical trials. Such targeted drugs offer superior efficacy with less risk of side effects compared to existing options. Their approval and commercialization in major markets will provide a significant boost to the asthma segment in the coming years.

Insights, By Treatment: Widespread Adoption of Anti-allergy Drugs Dominates Treatment Segment

The treatment segment includes anti-allergy drugs and immunotherapy. The anti-allergy drugs sub-segment is estimated to hold 82.4% of the market share in 2024 owing to their widespread adoption for treating different types of allergies. Allergic disorders often require long-term pharmacological intervention to control symptoms. Drugs from several classes like antihistamines, decongestants, leukotriene inhibitors, and mast cell stabilizers form the mainstay of treatment. Among these, oral antihistamines are among the most commonly used medications worldwide for relieving common allergic symptoms such as sneezing, itchy eyes and nose. The segment sees major growth due to the continuous development and approval of novel anti-allergy drugs with improved safety profiles. For example, newer generation non-sedating antihistamines have gained popularity as they cause fewer drowsiness side effects than older formulations. Also, combination therapies that incorporate other classes of drugs into a single medication provide better symptom relief with just one intake. Self-administration of oral drugs also adds to convenience compared to other modes like allergen immunotherapy requiring periodic physician supervision. These factors consolidate the leading position of anti-allergy drugs in the treatment segment.

Insights, By Distribution Channel: Hospital Pharmacies Lead Distribution on Back of Expanding Services

The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies sub-segment is estimated to hold 34.2% of the market share in 2024 owing to their increasing role beyond mere drug dispensing. Hospitals function as the frontline contact point for many patients experiencing exacerbation of allergic conditions. Severe cases often necessitate in-patient admission and administration of specialized drugs through the intravenous route under medical supervision. The segment is witnessing strong growth aided by hospital pharmacies expanding their service portfolio to include outsourced compounding of personalized medications, allergy testing facilities and patient education programs. This enhances accessibility to specialized care and strengthens adherence to long-term drug regimens. The shift towards value-based care is also driving many health systems to invest more resources in establishing comprehensive allergy centers and specialty clinics within their hospital pharmacy divisions. This allows for streamlined delivery of multi-disciplinary services from diagnosis to ongoing treatment under a single umbrella. Such a holistic model optimizes outcomes for allergic patients while boosting pharmacy revenues. These favorable trends fuel the prominence of hospital pharmacies as the leading distribution network.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global allergy treatment market and is estimated to hold 38.5% of the market share in 2024. Strong uptake of allergy immunotherapy and the wide availability of generic drugs have supported market growth. The region is home to most leading global pharmaceutical companies with large allergy portfolios. These companies carry out extensive R&D activities and frequently introduce new products, ensuring patients have access to the latest treatment options. Additionally, high awareness regarding allergies and their management has eased treatment-seeking behavior. However, price controls pose pricing challenges, pushing manufacturers to offer value-based offerings.

Asia Pacific is expected to record the highest growth, led by China, India and other developing nations. This can be attributed to improving healthcare infrastructure, rapid economic expansion, and growing medical tourism in these countries. Greater exposure to pollutants and changing lifestyles have contributed to rising allergy prevalence. Local manufacturers are strengthening their generic drug production to meet the needs of price-sensitive consumers. Over-the-counter drugs are also more accessible due to lenient regulations. This has boosted self-medication and made first-line therapies more affordable. International players are focusing on these emerging markets by tying up with local partners or setting up own manufacturing facilities. They view it as a high-potential region to tap into future demand.

Market Report Scope

Key Developments

• On February 16, 2024, Genentech, Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy
• On January 24, 2024, Dr Reddy’s Laboratories Ltd., a pharmaceutical company, announced that it had launched allergy medication, Histallay, into the U.K. for general sale
• In August 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company, announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the U.S. RYALTRIS is approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older
• In March 2021, ALK-Abelló A/S, a pharmaceutical company, announced its submission of a registration application in China, under National Medical Products Administration (NMPA), a Chinese agency for regulating drugs and medical devices, for its ACARIZAX, a house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet

*Definition: An allergy is a reaction by the immune system to something that does not bother most other people. An allergy occurs when a person reacts to substances in the environment that are harmless to most people. These substances are known as allergens and are found in dust mites, pollen, pets, insects, mold, ticks, foods and some drugs. Allergy symptoms rage from mild rash to hive, runny nose, itchiness, and watery red eyes, to life threatening.

Market Segmentation

• Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Eye Allergy
  • Asthma
  • Rhinitis
  • Skin Allergy
  • Food Allergies
  • Others
•  Treatment Insights (Revenue, USD Bn, 2019 - 2031)
  • Anti-allergy Drugs
  • Immunotherapy
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Sanofi
  • Novartis
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Stallergenes Greer
  • Dermapharm Holding SE
  • Nicox
  • Allergy Therapeutics
  • AbbVie Inc. 
  • Teva Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • ALK-Abelló A/S
  • Bausch Health Companies Inc.
  • GLENMARK PHARMACEUTICALS LTD. 
  • Perrigo Company plc
  • Dr Reddy’s Laboratories Ltd.